Huasheng Chang is the most popular secondary stocks in the stock market recently, and even become the market speculation direction standard, Huasheng Chang by the market attention, this time people again put their eyes on Huasheng Chang, this time not because of the stock, but because of the special relationship between the chairman of the board of directors and the four female directors,
According to the big V Hou An Yang posting broke the news: ? Huashengchang, China's most bullish listed company! Where is the bull? It's not the recent bullish share price. Rather, it is its enviable board of directors, only the chairman of the board is a man, the other 4 directors are women! And these 4 female directors, respectively, is the male chairman of the board: the first wife, second wife, third wife, fourth wife, are not licensed kind, and all for the chairman of the next generation. No wonder the chairman of the board of directors in the listing roadshow such a statement: no hardship on the road to business, full of happiness.
The shareholders are worried about their own interests at the same time, the melon masses are also wondering how Huasheng Chang is a bullish stock, which is not a problem? A bullish stock priceAccording to relevant information, by the impact of the epidemic global stock market in general is not optimistic, April 28, listed company Huashengchang released a quarterly performance report, quarterly revenue of 210 million, an increase of 90% year-on-year growth, attributable to the shareholders of the listed company's net profit of 89,580,000 yuan, an increase of 90% year-on-year. This performance report makes Huashengchang open after 6 stops, become the leading stocks of the sub-new shares. may 22, still soaring 7%, the highest share price rose to 75 yuan, and then fell back to 69 yuan.
Second, performance growth is inseparable from the environmentHuashengchang performance growth is mainly due to the new crown epidemic, according to public information, Huashengchang was founded in 1991, is specialized in independent design, research and development, production and sales of various types of measuring instruments in one of the high-tech enterprises, has successfully developed infrared camera, non-contact body thermometer series of products with independent intellectual property rights. These series of products is the epidemic during the much-needed medical equipment, his self-production and self-sales let Huashengchang stood a head start.
After the new coronary pneumonia, due to the time node occurred in the Spring Festival, a large number of production of medical equipment manufacturers did not start, and the market above the demand for urgent and large, this huge gap leads to a variety of medical products on the market as well as the price of raw materials for medical products skyrocketed, in terms of the cheapest masks, the factory price of more than 20 cents from the usual price, soaring to more than a dollar, the price of related raw materials is more than three times a day, the price of raw materials is more than one. Related raw material prices are three changes a day, many individuals in this period only by selling masks to get a huge profit, individuals and so on, as a non-contact infrared thermometer products and infrared thermal imaging products manufacturers are natural to earn a lot of money.
Huashengchang received more domestic orders after the outbreak. In Huasheng Chang was listed in Shenzhen epidemic prevention and control of key materials production enterprises after the number of domestic orders is to increase. When the domestic epidemic trend stabilized, the epidemic abroad and a full outbreak, in addition to a very few individual countries have not been spared, the lack of medical products in various countries will focus on China's medical production enterprises, which also includes Huasheng Chang, making Huasheng Chang in the domestic orders become less, and then received a large number of orders to the foreign countries, which makes its performance growth has been a rapidly rising The trend.
The relationship between the chairman of the board of directors and four female directors will certainly be concerned by all aspects, although in the prospectus clearly: Yuan Jianmin and Che Haixia there is no concerted action arrangements between the two sides in accordance with their respective holdings of shares to exercise the rights of shareholders, decision-making and management in the issuer did not form a concerted action relationship. But the real situation is so? Is there a concerted action relationship with the other three female directors in decision-making and management? Also remains a mystery, I wonder if the CIRC will intervene? Let's wait and see what happens,